AVANOS MEDICAL, INC. (AVNS) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-24

Key Insights

CFO Scott Galovan sold 4,228 shares at $24.64 per share on April 22, 2026, through mandatory tax withholding upon vesting of restricted stock units rather than a discretionary stock sale, indicating no negative sentiment about company prospects.
The transaction resulted from vesting of 12,225 time-based restricted share units (TRSUs) awarded exactly one year prior, with only 34.6% of vested shares retained after tax obligations, showing standard equity compensation mechanics.
Galovan maintains a direct beneficial ownership position of 135,596 shares post-transaction, demonstrating continued material stake in the company aligned with shareholder interests.

Want the newest filings?

This analysis covers the filing from 2026-04-24. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-24

SVP of Operations Sigfrido Delgado acquired 4,264 shares at $24.64 through vesting of time-based restricted stock units (TRSUs) on April 22, 2026, with 12,036 shares surrendered for tax withholding obligations, indicating a net acquisition of 4,264 shares.
Following this transaction, Delgado maintains direct beneficial ownership of 55,741 common shares, demonstrating sustained equity stake alignment with company performance as a senior executive.
The TRSU vesting represents standard equity compensation practice for senior management and does not indicate discretionary insider buying or selling activity, limiting conclusions about management's confidence in stock direction.

Filed: 2026-04-16

David Pacitti, the CEO of AVANOS MEDICAL, INC., disposed of 21,194 shares of common stock by surrendering them to the issuer to satisfy tax withholding obligations upon the vesting of time-based restricted share units (TRSUs).
The TRSUs were awarded to Pacitti on April 14, 2025 and vested on April 14, 2026, with each TRSU being the economic equivalent of one share of common stock.
Following the reported transaction, Pacitti continues to beneficially own 322,194 shares of AVANOS MEDICAL, INC. common stock.

Filed: 2026-03-17

The SEC Form 4 filing shows that Sigfrido Delgado, the SVP of Operations at AVANOS MEDICAL, INC. (AVNS), acquired 15,886 time-based restricted share units (TRSUs) and 37,520 stock options, vesting over the next 3 years. This indicates the company is incentivizing its senior leadership through equity-based compensation.
Delgado's total beneficial ownership of AVNS stock increased to 60,005 shares, suggesting he has a significant stake in the company and is aligned with shareholders' interests.
The timing of the option grant, with a 10-year expiration period, suggests the company is bullish on its long-term prospects and is seeking to retain and motivate its key executive.

Filed: 2026-03-17

John Joseph Hurley, the Principal Accounting Officer of Avanos Medical, Inc., acquired 2,211 time-based restricted share units (TRSUs) that will vest over the next three years, indicating his commitment to the company's long-term success.
Hurley's direct beneficial ownership of Avanos Medical's common stock increased to 13,592 shares following this transaction, further aligning his interests with those of the company's shareholders.
The TRSU award is part of Avanos Medical's 2021 Long Term Incentive Plan, which suggests the company is focused on incentivizing and retaining key personnel through equity-based compensation.

Filed: 2026-03-17

The reporting person, Scott Michael Galovan, the SVP and Chief Financial Officer of AVANOS MEDICAL, INC., has acquired 29,481 shares of the company's common stock through time-based restricted share units (TRSUs) that will vest over the next 3 years.
Galovan has also been granted 69,630 employee stock options that will vest over the next 3 years, indicating the company's commitment to incentivize and retain its key executive.
The total number of shares beneficially owned by Galovan has increased to 139,824, demonstrating his alignment with the company's long-term success.

Filed: 2026-03-17

David Pacitti, the Chief Executive Officer of AVANOS MEDICAL, INC., has been granted 101,341 time-based restricted share units (TRSUs) that will vest over the next three years.
Pacitti has also been granted 239,354 stock options that will vest over the next three years, providing him with a significant long-term incentive to drive the company's performance.
The insider buying activity indicates Pacitti's confidence in the company's future and alignment with shareholders' interests.

Filed: 2026-03-11

John Joseph Hurley, the Principal Accounting Officer of AVANOS MEDICAL, INC., surrendered 226 shares of common stock to the company to satisfy tax withholding obligations upon the vesting of 647 time-based restricted share units.
The vesting of these restricted share units suggests continued alignment between Hurley's incentives and the company's long-term performance.
The transaction was a relatively small one, with Hurley still holding 11,381 shares of AVNS stock after the transaction.

Filed: 2026-03-11

The reporting person, Scott Michael Galovan, who is the SVP and Chief Financial Officer of Avanos Medical, Inc. (AVNS), surrendered 1,119 shares of common stock to the issuer to satisfy tax withholding obligations upon the vesting of 3,235 time-based restricted share units (TRSUs).
The transaction occurred on March 9, 2026, and Galovan now beneficially owns 110,343 shares of Avanos Medical's common stock directly.
This routine transaction appears to be related to the vesting of Galovan's equity-based compensation and does not indicate any significant change in his overall ownership position or investment stance.

Filed: 2026-03-10

The reporting person, John Joseph Hurley, is the Principal Accounting Officer of Avanos Medical, Inc. and has filed this Form 4 to report changes in his beneficial ownership of the company's common stock.
Hurley acquired 919 performance-based restricted share units (PRSUs) that vested on March 6, 2026, and he surrendered a total of 676 shares to the issuer to satisfy tax withholding obligations upon the vesting of the PRSUs and time-based restricted share units (TRSUs).
The transaction details suggest insider activity related to equity compensation, which could indicate alignment between management and shareholder interests.

Filed: 2026-03-10

The reporting person, Scott Michael Galovan, is the SVP and Chief Financial Officer of AVANOS MEDICAL, INC. (AVNS), indicating his key role within the company.
Galovan acquired 5,907 performance-based restricted share units (PRSUs) on March 6, 2026, which vested on the same date, suggesting alignment between his compensation and company performance.
Galovan sold 5,454 shares to cover tax withholding obligations related to the vesting of his PRSUs and time-based restricted share units (TRSUs), indicating he is actively managing his equity position.

Other reports for AVANOS MEDICAL, INC.

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.